Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease

Abstract

A method for inhibiting the effects of cardiovascular disorders and diseases in a host susceptible to or suffering from a cardiovascular disorder or disease comprising administering to the host, a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a therapeutically effective amount of a second substance characterized as simulating an arginine-like effect; and a formulation for use in treating a host susceptible to or suffering from the effects of cardiovascular disorders and diseases comprising a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a second substance characterized an simulating an arginine-like effect, an described.

What is claimed is:  
     
       1. A method for treating a patient susceptible to or suffering from at least one of atherosclerosis, arteriosclerosis, congestive heart failure, stroke, arterial dysfunction, re-stenosis, hypertension, smooth muscle cell hydrophy, thrombogenicity, clotting disorders, platelet disorders, myocardial infarction, cerebrovascular ischemia, or peripheral vascular ischemia, said method comprising orally administering to said patient a therapeutically effective amount of a first substance selected from the group consisting of heparin, heparin sulfate, taprostene, prostacyclin, and physiologically acceptable salts thereof, and a therapeutically effective amount of a second substance selected from the group consisting of arginine, arginine sulfate, and physiologically acceptable salts thereof. 
     
     
       2. The method of claim  1  wherein said first substance is exogenous heparin. 
     
     
       3. The method of claim  1  wherein said first substance is dispersed in a physiologically acceptable carrier. 
     
     
       4. The method of claim  3  wherein said physiologically acceptable carrier is water. 
     
     
       5. The method of claim  1  wherein said first substance is administered subcutaneously, intravenously, rectally, transdermal or intra pulmonary. 
     
     
       6. The method of claim  1  wherein said second substance is arginine, a functional analog of arginine, a physiological acceptable salt of arginine, or a physiologically acceptable salt of a functional analog of arginine. 
     
     
       7. The method of claim  6  wherein said second substrate is exogenous L-arginine. 
     
     
       8. The method of claim  1  wherein said second substance is dispersed in a physiologically acceptable carrier. 
     
     
       9. The method of claim  8  wherein said physiologically acceptable carrier is water. 
     
     
       10. The method of claim  1  wherein said second substance is administered subcutaneously, intravenously, rectally, transdermally or intra pulmonary. 
     
     
       11. The method of claim  1  wherein said first substance and said second substance are co-administered orally. 
     
     
       12. The method of claim  1  wherein said therapeutically effective amount of the first substance is characterized as containing about 2000 to 200,000 units of heparin, heparin sulfate, taprostene, prostacyclin, or a physiologically acceptable salt thereof. 
     
     
       13. The method of claim  1  wherein said therapeutically effective amount of the second substance comprises about 500 to 50,000 mg arginine, arginine sulfate, or a physiologically acceptable salt thereof. 
     
     
       14. A method of treating cardiovascular disease comprising the step of administering a mixture of arginine and heparin in therapeutic proportions. 
     
     
       15. The method of claim  14 , for the treatment of angina pectoris. 
     
     
       16. The method of claim  14 , for treatment of cardiovascular systems. 
     
     
       17. The method of claim  14 , for oral administration.